-
Subject Areas on Research
-
A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial.
-
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.
-
A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder.
-
A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study.
-
Acceptability of second-step treatments to depressed outpatients: a STAR*D report.
-
Acute 5-HT reuptake blockade potentiates human amygdala reactivity.
-
Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care.
-
Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression.
-
An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.
-
An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder.
-
Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial.
-
Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report.
-
Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study.
-
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.
-
Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder.
-
Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.
-
Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort.
-
Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.
-
Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.
-
Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC).
-
Bupropion in the treatment of outpatients with asthma and major depressive disorder.
-
CYP2C19 variation and citalopram response.
-
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
-
Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report.
-
Changes in depressive symptoms and social functioning in the sequenced treatment alternatives to relieve depression study.
-
Citalopram and quality of life in lung transplant recipients.
-
Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D.
-
Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study.
-
Cognitive Behavioral Insomnia Therapy for Those With Insomnia and Depression: A Randomized Controlled Clinical Trial.
-
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.
-
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.
-
Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.
-
Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder.
-
Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.
-
Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
-
Depression outcomes of Spanish- and english-speaking Hispanic outpatients in STAR*D.
-
Depression treatment in patients with general medical conditions: results from the CO-MED trial.
-
Depression, IV: STAR*D treatment trial for depression.
-
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
-
Differential regulation of MeCP2 phosphorylation in the CNS by dopamine and serotonin.
-
Diurnal mood variation in outpatients with major depressive disorder.
-
Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial.
-
Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study.
-
Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes.
-
Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
-
Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report.
-
Effect of age at onset on the course of major depressive disorder.
-
Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
-
Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial.
-
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial.
-
Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants.
-
Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting.
-
Escitalopram in specific phobia: results of a placebo-controlled pilot trial.
-
Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.
-
Escitalopram related edema in a patient with Hashimoto's thyroiditis.
-
Escitalopram treatment of trichotillomania.
-
Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder.
-
Ethnicity/race and outcome in the treatment of depression: results from STAR*D.
-
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
-
Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report.
-
Family history of completed suicide and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study.
-
Family history of depression and therapeutic outcome: findings from STAR*D.
-
Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients.
-
Genetic markers of suicidal ideation emerging during citalopram treatment of major depression.
-
Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients.
-
Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.
-
High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial.
-
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
-
Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report.
-
Income and attrition in the treatment of depression: a STAR*D report.
-
Increase in work productivity of depressed individuals with improvement in depressive symptom severity.
-
Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression.
-
Inflammation-Induced Histamine Impairs the Capacity of Escitalopram to Increase Hippocampal Extracellular Serotonin.
-
Insured and non-insured depressed outpatients: how do they compare?
-
International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
-
Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report.
-
Limitations in efficacy of antidepressant monotherapy.
-
Longer term benefits of exercise and escitalopram in the treatment of anxiety in patients with coronary heart disease: Six month follow-up of the UNWIND randomized clinical trial.
-
MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression.
-
Medication augmentation after the failure of SSRIs for depression.
-
Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients.
-
Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics.
-
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.
-
Motor cortex excitability after vagus nerve stimulation in major depression.
-
Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication.
-
Naturalistic study of the early psychiatric use of citalopram in the United States.
-
Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial.
-
Pain in depression: STAR*D study findings.
-
Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report.
-
Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study.
-
Pharmacogenetics studies in STAR*D: strengths, limitations, and results.
-
Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.
-
Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
-
Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study.
-
Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
-
Prediction of nonremission to antidepressant therapy using diffusion tensor imaging.
-
Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report.
-
Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D.
-
Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis.
-
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
-
Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care.
-
Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms.
-
Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.
-
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
-
Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.
-
Retention and attrition among African Americans in the STAR*D study: what causes research volunteers to stay or stray?
-
SLC6A4 variation and citalopram response.
-
Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder.
-
Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.
-
Selective serotonin reuptake inhibitors for fibromyalgia syndrome.
-
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
-
Sex differences in platelet reactivity and cardiovascular and psychological response to mental stress in patients with stable ischemic heart disease: insights from the REMIT study.
-
Sex differences in response to citalopram: a STAR*D report.
-
Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial.
-
Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort.
-
TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.
-
The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation.
-
The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort.
-
The Quick Inventory of Depressive Symptomatology-Self-report: a psychometric evaluation in patients with asthma and major depressive disorder.
-
The STAR*D study: treating depression in the real world.
-
The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
-
The impact of nonclinical factors on care use for patients with depression: a STAR*D report.
-
The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study.
-
The selective serotonin reuptake inhibitor citalopram induces the storage of serotonin in catecholaminergic terminals.
-
Therapy for mental stress-induced myocardial ischemia--reply.
-
Toward a Definition of "No Meaningful Benefit" From Antidepressant Treatment: An Equipercentile Analysis With Cross-Trial Validation Across Multiple Rating Scales.
-
Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial.
-
Treatment of social anxiety disorder with citalopram.
-
Treatment outcome variation between depression symptom combinations in the STAR*D study.
-
Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.
-
Usefulness of Myocardial Annular Velocity Change During Mental Stress to Predict Cardiovascular Outcome in Patients With Coronary Artery Disease (From the Responses of Mental Stress-Induced Myocardial Ischemia to Escitalopram Treatment Trial).
-
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.
-
What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression.
-
What predicts attrition in second step medication treatments for depression?: a STAR*D Report.
-
[A new quality of the therapy of anxiety and depression--escitalopram].
-
Keywords of People